Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Advanced Non-squamous NSCLC Clinical Trial

Official title:
A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control.

Status Recruiting

Clinical Trial Summary

Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.

Clinical Trial Description

Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET. ;

Study Design

Related Conditions & MeSH terms

Advanced Non-squamous NSCLC

Clinical Trial Details

NCT number	NCT03768037
Study type	Interventional
Source	Guangdong Association of Clinical Trials
Contact	Xiaoqing Liu
Phone	86-010-89509324
Email	liuxiaoqing@csco.org.cn
Status	Recruiting
Phase	Phase 4
Start date	November 26, 2018
Completion date	November 26, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04325698` - A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC	Phase 3
Terminated	`NCT00369070` - A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC	Phase 2
Not yet recruiting	`NCT03778853` - Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)	Phase 4